HaemoneticsTEG doing well
Under Hospital business, the Hemostasis Management product line saw strong growth in the past few quarters. The product line continued to be benefit from strong capital equipment sales in the United States and sales of TEG cartridges in Europe. In January, the FDA issued a new guidance on viscoelastic testing mentioning the use of TEG devices for improved patient care during the pandemic. Considering the pandemic scenario and the higher need to treat COVID-19 patients, we expect these devices to have registered robust sales during the fiscal fourth-quarter as well, thus adding to overall growth.
from May 12
https://finance.yahoo.com/news/haemonetics-hae-report-q4-earnings-102210108.html